Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
Grantová podpora
LX22NPO5102
National Institute for Cancer Research Project
EuropeanUnion-Next Generation EU
Czech Leukemia Study Group for Life (CELL)
PubMed
39044120
DOI
10.1111/bjh.19670
Knihovny.cz E-zdroje
- Klíčová slova
- acute myeloid leukaemia, antifungal prophylaxis, fungal infection, venetoclax and azacitidine,
- MeSH
- akutní myeloidní leukemie * farmakoterapie komplikace MeSH
- antifungální látky * terapeutické užití aplikace a dávkování MeSH
- azacytidin * aplikace a dávkování terapeutické užití MeSH
- bicyklické sloučeniny heterocyklické * aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mykózy * prevence a kontrola etiologie MeSH
- protokoly protinádorové kombinované chemoterapie * škodlivé účinky terapeutické užití aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sulfonamidy * aplikace a dávkování terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Názvy látek
- antifungální látky * MeSH
- azacytidin * MeSH
- bicyklické sloučeniny heterocyklické * MeSH
- sulfonamidy * MeSH
- venetoclax MeSH Prohlížeč
Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
Department of Haematology and Oncology University Hospital Pilsen Pilsen Czech Republic
Department of Oncohematology Comenius University and National Cancer Institute Bratislava Slovakia
Faculty of Medicine Center of Excellence CREATIC Masaryk University Brno Czech Republic
Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria
Medical Department Hematology Charles University General Hospital Prague Czech Republic
Zobrazit více v PubMed
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629.
Stemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022;9:e361–e373. https://doi.org/10.1016/S2352‐3026(22)00073‐4
Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63:1934–1941. https://doi.org/10.1080/10428194.2022.2047964
On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, et al. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022;197:63–70. https://doi.org/10.1111/bjh.18051
Lee R, Cho SY, Lee DG, Choi H, Park S, Cho BS, et al. Infections of venetoclax‐based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis. Cancers (Basel). 2021;13:6285. https://doi.org/10.3390/cancers13246285
Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019;23:4043–4049. https://doi.org/10.1182/bloodadvances
Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, et al. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study. Am J Hematol. 2022;97:E422–E425. https://doi.org/10.1002/ajh.26707
Hall VG, Tang K, Kumar D, Rotstein C, Chow S, Chan SM, et al. Breakthrough invasive fungal infection after coadministration of venetoclax and voriconazole. Open Forum Infect Dis. 2023;10:ofad134. https://doi.org/10.1093/ofid/ofad134
Sciumè M, Bosi A, Canzi M, Ceparano G, Serpenti F, de Roberto P, et al. Real‐life monocentric experience of venetoclax‐based regimens for acute myeloid leukemia. Front Oncol. 2023;13:1149298. https://doi.org/10.3389/fonc.2023.1149298
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, et al. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021;127:2489–2499. https://doi.org/10.1002/cncr.33508
De la Garza‐Salazar F, Colunga‐Pedraza PR, Gómez‐Almaguer D, García‐Zárate VA, Gómez‐De León A. Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: a phase 2 study. Leuk Res. 2023;133:107373. https://doi.org/10.1016/j.leukres.2023.107373
Teh CE, Peng H, Luo MX, Tan T, Trussart M, Howson LJ, et al. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells. Blood Adv. 2023;7(12):2733–2745. https://doi.org/10.1182/bloodadvances.2022008221
